These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32372569)

  • 1. The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.
    Goldstein DA; Mayer C; Shochat T; Reinhorn D; Moore A; Sarfaty M; Yerushalmi R; Goldvaser H
    Cancer Med; 2020 Jul; 9(13):4603-4612. PubMed ID: 32372569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the OncotypeDX score: validation of an inexpensive estimation tool.
    Eaton AA; Pesce CE; Murphy JO; Stempel MM; Patil SM; Brogi E; Hudis CA; El-Tamer M
    Breast Cancer Res Treat; 2017 Feb; 161(3):435-441. PubMed ID: 27928699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
    Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
    Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
    Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE
    J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
    Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
    Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
    Mutonga M; Speedy S; Rademaker A; Liu D; Uthe R; Jain S; Gradishar WJ; Flaum L; Santa-Maria CA
    Breast Cancer Res Treat; 2019 Jul; 176(1):95-100. PubMed ID: 30977026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
    Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
    Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center.
    Deme D; Tamaskovics BF; Jammoul N; Kovács S; Kayode EO; Grice JW; Telekes A
    Pathol Oncol Res; 2024; 30():1611735. PubMed ID: 38689824
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.
    Zeng Y; Li Q; Qin T; Li S; Jin L; Wu J; Chen K; Deng H; Rao N; Liu Q; Su F; Jia W; Yao H
    Anticancer Res; 2017 Aug; 37(8):4539-4547. PubMed ID: 28739750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
    Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
    Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer.
    Batra A; Nixon NA; Roldan-Urgoiti G; Hannouf MB; Abedin T; Hugh J; King K; Bigras G; Steed T; Lupichuk S
    Cancer Treat Res Commun; 2021; 28():100401. PubMed ID: 34091374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
    Karsten M; Stempel M; Radosa J; Patil S; King TA
    Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.